0 Health - March 7, 2016Obesity linked to dramatic rise in liver diseaseAlarming new statistics show that 1 in 4 Canadians may be affected by liver disease TORONTO, March 7, 2016 /CNW/ […]Read More
0 Health - March 7, 2016Sakto Corporation Sponsors Irish-Canadian Event to Benefit Local Healthcare CharityOTTAWA, Ontario, March 7, 2016 /CNW/ — Sakto Corporation, a real estate holding and investment firm based in Ottawa, is sponsoring the […]Read More
0 Health - March 7, 2016Aflac Incorporated Presentation Available for On-Demand Viewing at VirtualInvestorConferences.comCOLUMBUS, Ga., March 7, 2016 /CNW/ — Aflac Incorporated (NYSE: AFL) announced today that the presentation from March 3, 2016, […]Read More
0 Health - March 7, 2016Bionik Laboratories Enters into Merger Agreement to Acquire Interactive Motion Technologies, Inc. (IMT)— Bionik to acquire all of IMT’s outstanding stock; IMT shareholders to receive shares of Bionik common stock — Bionik […]Read More
0 Health - March 7, 2016Major Liver Cancer Study Completes Palliative Cohort EnrolmentPalliative Group of SORAMIC Study on Treatment of Locally Advanced Primary Liver Cancer with SIR-Spheres® Y-90 resin microspheres followed by […]Read More
0 Health - March 7, 2016Covalon Announces Issuance of Stock OptionsMISSISSAUGA, ON, March 7, 2016 /CNW/ – Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV), an advanced medical technologies company, […]Read More
0 Health - March 7, 2016Valeant Pharmaceuticals To Hold Conference Call On March 15, 2016LAVAL, Quebec, March 7, 2016 /CNW/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it plans to […]Read More
0 Health - March 7, 2016New Novartis data presented at AAD reveals Cosentyx® is superior to Stelara® in delivering long-lasting skin clearance (PASI 90) for psoriasis patients at 52 weeks(1)Cosentyx® delivered and sustained skin clearance (PASI 90) in nearly 8 out of 10 moderate-to-severe psoriasis patients after 52 weeks […]Read More
0 Health - March 7, 2016Merus Completes Acquisition of Surgestone®, Provames®, Tredemine® and Speciafoldine® Rights from SanofiTORONTO, March 7, 2016 /CNW/ – Merus Labs International Inc. (“Merus” or the “Company”) [TSX: MSL, NASDAQ: MSLI] announced today that it […]Read More
0 Health - March 7, 2016Operation Smile Canada Elects Mr Al Hildebrandt to Board of DirectorsTORONTO, March 7, 2016 /CNW/ – Operation Smile Canada Foundation (“OSCF”) raises funds to provide surgeries for children with cleft lip […]Read More